Join to view full profile
3303 S Bond AveSte CH10UPortland, OR 97239
Phone+1 503-494-4779
Dr. Kopp is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ryan Kopp is an urologist in Portland, OR and is affiliated with VA Portland Healthcare System. He received his medical degree from Indiana University School of Medicine, residency training at UC San Diego, and completed his urologic oncology fellowship at Memorial Sloan Kettering Cancer Center. He has held an appointment at Oregon Health & Science University and the VA Portland Healthcare System since 2015. He specializes in urologic oncology and is experienced in multidisciplinary care of genitourinary cancers (prostate, kidney, testicular, bladder), genetic research, cancer early detection, and clinical trials.
Education & Training
Oregon Health & Science UniversityMCR, Clinical Research, 2022 - 2024
Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 2013 - 2015
University of California (San Diego) Medical CenterResidency, Urology, 2009 - 2013- University of California (San Diego) Medical CenterResidency, Surgery, 2007 - 2009
Indiana University School of MedicineClass of 2007
Certifications & Licensure
OR State Medical License 2015 - 2027
NY State Medical License 2012 - 2016
CA State Medical License 2009 - 2013
American Board of Urology Urology
Clinical Trials
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss Start of enrollment: 2024 May 31
- S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Start of enrollment: 2017 Feb 24
- Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants Start of enrollment: 2016 Jun 13
Publications & Presentations
PubMed
- The Impact of Medicaid Expansion on Insurance Coverage and Metastatic Disease at Diagnosis for Racial and Ethnic Subgroups Diagnosed With Prostate Cancer.David Schroeder, Solange Bassale, Murray J Bartho, Vanessa Le, Brian Duty
Urology Practice. 2026-07-01 - Reply by Authors.David Schroeder, Solange Bassale, Murray J Bartho, Vanessa Le, Brian Duty
Urology Practice. 2026-07-01 - Trans-cytolemmal water exchange in prostate manifest via DCE-MRI.Xin Li, Ryan P Kopp, William D Rooney, Charles S Springer Jr, Fergus V Coakley
Magma. 2026-04-15
Press Mentions
Open Clinical Trials for Patients with Prostate CancerMarch 10th, 2025
Grant Support
- Precision Neoadjuvant Therapy for High Risk Localized Prostate Cancer with PTEN LossPORTLAND VA MEDICAL CENTER2024–2028
- Integration of Magnetic Resonance Imaging and Protein Biomarkers for Identification of Aggressive Prostate CancerCDMRP Prostate Cancer Research ProgramPresent
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
